NCT02885012View on ClinicalTrials.gov

Crossover Study From Macitentan or Bosentan Over to Ambrisentan

PHASE4TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

July 7, 2017

Study Completion Date

July 7, 2017

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Ambrisentan

At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.

Trial Locations (2)

29425

Medical University of South Carolina, Charleston

70121

Ochsner Medical Center, New Orleans

Sponsors

Collaborators (1)

Ochsner Health System
All Listed Sponsors
collaborator

Ochsner Health System

OTHER

lead

Medical University of South Carolina

OTHER